-
-
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States.
-
-
Hospitalized patients with terminal illnesses often feel abandoned by their physicians at the end of their lives. Their physicians might experience a lack of closure that is unsettling.
-
Mistakes happen even to the best clinicians. This is why hospitals increasingly are relying on checklists and other tools to assist clinicians in the discharge process.
-
A study of a patient safety strategy at Boston's Brigham & Women's Hospital that incorporated bar-code verification technology within an electronic medication-administration system (bar-code eMAR) showed a significant reduction in errors, according to an article published in the May 6, 2010, issue of the New England Journal of Medicine.
-
Your ED patient's bad outcome might have nothing to do with the fact that he or she was held in the hallway while awaiting an inpatient bed. However, it could impact the outcome of subsequent litigation against the ED.
-
When a hospital in downtown Knoxville, TN, closed and volume soared at other nearby hospitals, two hospitals in the Covenant Health System joined forces to develop a systematic approach to capacity management that allows each hospital to create variances in the process to meet its individual needs.
-
In just a few years, your hospital could lose a significant amount of money if its 30-day readmission rate is higher for Medicare patients with certain diagnoses than the rate at other hospitals.